GlassScriptPhysician profile
Steven H Stokes
NPI 1780752881
$7,294.55
in general payments reported to CMS, 2019-2025
68 companies · $1,691 in 2025
The $1,691 reported for 2025 was more than what 90% of Therapeutic Radiology providers received nationally (typical 2025 total: $179).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.49 · 2021: $1,236 · 2022: $983 · 2023: $1,557 · 2024: $1,781 · 2025: $1,691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,950 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,949.55 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $711.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $573.08 | 2020-2025 | Imfinzi, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $453.22 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Genzyme Corporation | $361.70 | 2021-2025 | |
| Amgen INC. | $358.17 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $280.54 | 2021-2025 | Libtayo |
| Daiichi Sankyo INC. | $279.14 | 2020-2025 | Enhertu, Datroway |
| Eisai INC. | $275.47 | 2021-2025 | |
| Janssen Biotech, INC. | $267.77 | 2021-2025 | Tecvayli, Darzalex, Akeega |
| Incyte Corporation | $234.52 | 2021-2025 | Monjuvi, Zynyz, Jakafi |
| Astellas Pharma US INC | $215.04 | 2021-2025 | Vyloy, Xospata, Padcev |
| Celltrion USA INC. | $162.97 | 2025 | Vegzelma |
| E.R. Squibb & Sons, L.L.C. | $154.74 | 2023-2025 | Opdivo |
| Jazz Pharmaceuticals INC. | $153.31 | 2023-2025 | Zepzelca |
| Takeda Pharmaceuticals U.S.A., INC. | $152.06 | 2021-2025 | Ninlaro, Fruzaqla |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $141.48 | 2022-2025 | |
| Abbvie INC. | $127.71 | 2021-2025 | |
| Genentech USA, INC. | $123.66 | 2023-2025 | Lunsumio, Polivy, Columvi |
| Stemline Therapeutics INC. | $117.17 | 2023-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $116.50 | 2021-2023 | Jaypirca, Verzenio, Retevmo |
| Ipsen Biopharmaceuticals, INC | $114.99 | 2021-2025 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $99.06 | 2021-2025 | Jemperli, Ojjaara, Zejula |
| Aveo Pharmaceuticals, INC. | $97.00 | 2021-2024 | Fotivda |
| Emd Serono, INC. | $96.16 | 2021-2023 | Mavenclad, Tepmetko |
| Karyopharm Therapeutics INC. | $86.18 | 2022-2023 | Xpovio |
| Blueprint Medicines Corporation | $81.11 | 2021-2023 | Ayvakit |
| Seagen INC. | $78.13 | 2021-2023 | Padcev, Adcetris, Tivdak |
| Springworks Therapeutics, INC. | $71.19 | 2024-2025 | Ogsiveo |
| Beigene USA, INC. | $71.11 | 2022-2024 | Brukinsa |
| Pfizer INC. | $69.50 | 2023-2024 | |
| Mirati Therapeutics, INC. | $68.66 | 2023-2024 | Krazati |
| Pharmacosmos Therapeutics INC. | $66.77 | 2023-2024 | Monoferric, Cosela |
| Beone Medicines USA, INC. | $64.67 | 2025 | Brukinsa, Tevimbra |
| Coherus Oncology, INC. | $60.43 | 2022-2024 | |
| G1 Therapeutics, INC. | $58.45 | 2022-2023 | Cosela |
| Tempus Ai, INC | $54.03 | 2025 | Xt Cdx |
| Progenics Pharmaceuticals, INC. | $52.40 | 2021-2024 | Pylarify |
| Taiho Oncology, INC. | $51.04 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $50.93 | 2022-2024 | Tavalisse, Rezlidhia |
| Apellis Pharmaceuticals, INC. | $48.72 | 2023-2024 | Empaveli |
| Sobi, INC | $42.61 | 2024 | |
| Myriad Genetic Laboratories, INC. | $39.42 | 2021-2025 | Myrisk |
| Servier Pharmaceuticals LLC | $35.03 | 2021-2025 | |
| Novocure INC. | $31.40 | 2021-2025 | Optune Gio |
| Exelixis INC. | $30.62 | 2021-2023 | Cabometyx |
| Adc Therapeutics America, INC. | $29.91 | 2022-2023 | |
| Tersera Therapeutics LLC | $25.92 | 2021 | |
| Amneal Pharmaceuticals LLC | $24.20 | 2025 | Alymsys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.57 | 2021 | |
| Puma Biotechnology, INC. | $21.84 | 2025 | |
| Sun Pharmaceutical Industries INC. | $21.20 | 2023 | Yonsa, Odomzo |
| Agios Pharmaceuticals, INC. | $20.25 | 2024 | Pyrukynd |
| Acceleron Pharma, INC. | $20.17 | 2021 | |
| Dova Pharmaceuticals | $18.50 | 2021 | |
| Genmab U.S., INC. | $18.11 | 2023 | Epkinly |
| Immunogen, INC. | $17.68 | 2024 | Elahere |
| Corcept Therapeutics | $17.12 | 2025 | Korlym |
| Acrotech Biopharma INC. | $16.42 | 2023 | Beleodaq |
| Csl Behring | $15.28 | 2021 | |
| Heron Therapeutics, INC. | $15.23 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $15.12 | 2021 | |
| Celgene Corporation | $14.88 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.85 | 2021 | |
| Adaptive Biotechnologies Corporation | $13.83 | 2023 | Clonoseq |
| Sumitomo Pharma America, INC. | $13.75 | 2023 | Orgovyx |
| Kyowa Kirin, INC. | $13.54 | 2023 | Poteligeo |
| Global Blood Therapeutics, INC. | $12.75 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $12.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.